首页> 外文期刊>BioMed research international >Antileukotriene Reverts the Early Effects of Inflammatory Response of Distal Parenchyma in Experimental Chronic Allergic Inflammation
【24h】

Antileukotriene Reverts the Early Effects of Inflammatory Response of Distal Parenchyma in Experimental Chronic Allergic Inflammation

机译:抗白三烯逆转远端实质的炎症反应在实验性慢性过敏性炎症中的早期作用

获取原文
           

摘要

Aims. Compare the effects of montelukast or dexamethasone in distal lung parenchyma and airway walls of guinea pigs (GP) with chronic allergic inflammation.Methods. GP have inhaled ovalbumin (OVA group-2x/week/4weeks). After the 4th inhalation, GP were treated with montelukast or dexamethasone. After 72 hours of the 7th inhalation, GP were anesthetised, and lungs were removed and submitted to histopathological evaluation.Results. Montelukast and dexamethasone treatments reduced the number of eosinophils in airway wall and distal lung parenchyma compared to OVA group (P<0.05). On distal parenchyma, both treatments were effective in reducing RANTES, NF-κB, and fibronectin positive cells compared to OVA group (P<0.001). Montelukast was more effective in reducing eotaxin positive cells on distal parenchyma compared to dexamethasone treatment (P<0.001), while there was a more expressive reduction of IGF-I positive cells in OVA-D group (P<0.001). On airway walls, montelukast and dexamethasone were effective in reducing IGF-I, RANTES, and fibronectin positive cells compared to OVA group (P<0.05). Dexamethasone was more effective in reducing the number of eotaxin and NF-κB positive cells than Montelukast (P<0.05).Conclusions. In this animal model, both treatments were effective in modulating allergic inflammation and remodeling distal lung parenchyma and airway wall, contributing to a better control of the inflammatory response.
机译:目的比较孟鲁司特或地塞米松在患有慢性过敏性炎症的豚鼠远端肺实质和气道壁中的作用。 GP已吸入卵清蛋白(OVA组2x /周/ 4周)。第四次吸入后,用孟鲁司特或地塞米松治疗GP。第7次吸入72小时后,麻醉GP,取出肺并进行组织病理学评估。与OVA组相比,孟鲁司特和地塞米松治疗减少了气道壁和远端肺实质中的嗜酸性粒细胞数量(P <0.05)。在远端实质中,与OVA组相比,两种治疗均能有效减少RANTES,NF-κB和纤连蛋白阳性细胞(P <0.001)。与地塞米松治疗相比,孟鲁司特在减少远端实质组织中的趋化因子阳性细胞方面更有效(P <0.001),而在OVA-D组中IGF-I阳性细胞的表达降低更多(P <0.001)。与OVA组相比,孟鲁司特和地塞米松在气道壁上可有效减少IGF-I,RANTES和纤连蛋白阳性细胞(P <0.05)。地塞米松在减少嗜酸性粒细胞趋化因子和NF-κB阳性细胞方面比孟鲁司特更为有效(P <0.05)。在这种动物模型中,两种治疗均有效调节过敏性炎症并重塑远端肺实质和气道壁,从而有助于更好地控制炎症反应。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号